Thomas Chateau
Welcome,         Profile    Billing    Logout  
 5 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mathieu, Nicolas
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
PEREM, NCT04990258: A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC

Active, not recruiting
N/A
444
Europe
Subcutaneous infliximab CT-P13 Remsima®SC
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Celltrion
Inflammatory Bowel Diseases
06/24
09/24
DOPER, NCT05158517: VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study

Active, not recruiting
N/A
349
Europe
Subcutaneous vedolizumab
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Takeda
Inflammatory Bowel Diseases
03/24
03/25
Chateau, Thomas
DOPER, NCT05158517: VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study

Active, not recruiting
N/A
349
Europe
Subcutaneous vedolizumab
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Takeda
Inflammatory Bowel Diseases
03/24
03/25

Download Options